.Pharmacolibrary.Drugs.ATC.B.B03XA02 .Pharmacolibrary.Drugs.ATC.B.B03XA02| name: | DarbepoetinAlfa |
| ATC code: | B03XA02 | route: | intravenous |
| n-compartments | 2 |
Darbepoetin alfa is a synthetic analog of erythropoietin used to stimulate erythropoiesis. It is approved for the treatment of anemia associated with chronic kidney disease (CKD) and chemotherapy-induced anemia in cancer patients. It is longer-acting than recombinant human erythropoietin due to additional sialic acid groups.
Pharmacokinetic parameters in adults with chronic kidney disease after intravenous and subcutaneous administration. Subjects included both male and female patients, 18 to 75 years old, with stable renal function.
An, G, et al., & Veng-Pedersen, P (2017). Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing. Journal of pharmaceutical sciences 106(6) 1644–1649. DOI:10.1016/j.xphs.2017.02.001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28189627
Roberts, JK, et al., & Sherwin, CM (2015). Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy. Clinical pharmacokinetics 54(12) 1237–1244. DOI:10.1007/s40262-015-0286-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/25989868
Agoram, B, et al., & Sullivan, JT (2007). Population pharmacokinetics of darbepoetin alfa in healthy subjects. British journal of clinical pharmacology 63(1) 41–52. DOI:10.1111/j.1365-2125.2006.02752.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/16939525